{'fraction_non_alphanumeric': 0.027656477438136828, 'fraction_numerical': 0.008733624454148471, 'mean_word_length': 5.679611650485437, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Toll-like receptors: emerging targets of immunomodulation

Toll-like receptors (TLRs) were shown to play a critical role in the recognition and activation of pathogens by the innate immune system. Pathogen engagement of the TLR–myeloid differentiation protein 88 (MyD88) pathway favours the development of a protective T-helper (TH)1-biased T cell response. Interruption of TLR recognition or signalling has profound effects on protective immunity and enhances a TH2-biased immune response. Agonists or antagonists of specific TLRs have effects beyond infectious control and may represent a novel therapeutic for immunostimulation in vaccines, cancer, inflammatory disorders and allergy.